Description:
Neutalizing Monoclonal Antibodies Against SARS-CoV-2 for COVID-19 Screening and Treatment
Development of neutralizing monoclonal antibodies (mAbs) that bind to the spike glycoprotein on SARS-CoV-2.
The WHO declared COVID-19 a global pandemic as of March, 2020. The infection is caused by SARS-CoV-2, a beta coronavirus with 79.5% genome sequence identify to SARS-CoV. As of June, 2020. more than 400,000 people have died globally from COVID-19, and there remains no vaccine or approved therapeutic. The surface spike protein of SARS-CoV-2 binds ACE2 receptors on the surface of human cells. Once bound, the virus is able to enter the cell and translate RNA to produce more viruses. The SARS-CoV-2 envelope glycoprotein is a surface-exposed class-I fusion protein that has an ectodomain comprised of a receptor binding domain (RBD) subunit and a membrane-fusion subunit. Researchers at the Fred Hutch have developed neutralizing monoclonal antibodies capable of binding specific regions of the SARS-CoV-2 ectodomain. Drs. Stamatatos, McGuire, and Pancera have isolated 45+ monoclonal antibodies from serum samples derived from SARS-CoV-2 seropositive patients.
<ul>
<li> Could serve as an immediate therapeutic </li>
</li> These antibodies act as templates for vaccine development, or the development of screening tools and assays </li>
</li>Use within a cocktail approach to reduce viral escape </li>
</ul>
<ul>
<li> Fully-humanized neutralizing antibody validated in live virus</li>
<li>Blocks interaction with ACE2 receptor on human cells </li>
</ul>
The Global Respiratory Disease Vaccine Market is expected to grow from USD 18,236.13 Million in 2018 to USD 25,236.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 4.75%. The global COVID-19 diagnostics market accounted for USD 4.9 billion in 2020 and with a CAGR of 6.1%, is estimated to reach USD 8.3 billion by 2029.
<ul>
<li>Leonidas Stomatatos, PhD </li>
</li> Andrew McGuire, PhD </li>
</li> Marie Pancera, PhD </li>
</li> Vaccine and Infectious Disease Division </li>
</ul>
Preclinical <em>in vivo</em>
Patent Pending
20-158_Stomatatos_McGuire_Pancera_SARS-CoV-2 Neutralizing mAbs_NCSPDF.pdf
|COVID | Coronavirus | SARS-COV-2 | antibody | Neutralizing
SARS-CoV-2-Neutralizing-mAbs-20-158